Preventive Effect of Lactobacillus Fermentation Extract on Inflammation and Cytokine Production in Lipopolysaccharide-Induced Cystitis in Mice
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The effects of Lactobacillus fermentation extract (LFE) on cystitis induced by Escherichia coli lipopolysaccharide (LPS) in the mouse bladder were investigated by pathological analyses and measurement of the levels of tumor necrosis factor-alpha (TNF-) and interleukin-18 (IL-18).Materials and Methods: LFE was administered orally (5 g/L) to mice for 10 days after which the study group (n=12) received transurethral injection of 5 g/L LPS. The bladder tissue was then harvested after 24 hours and subjected to hematoxylin and eosin staining. A semi-quantitative score was used to evaluate inflammation (bladder inflammation index, BII). TNF- immunohistochemical staining and multiplex cytokine assays were also performed. TNF- and IL-18 levels were determined. The results were compared with those of the control group (n=12).Results: The BII in the control and study groups was 2.7±0.5 and 1.1±0.7, respectively, with the control group scores differing significantly from the study group scores (p<0.001). TNF- immunohistochemical staining results were similar. The TNF- levels determined by the multiplex cytokine assay were 2.82±1.35 pg/mg and 1.55±0.56 pg/mg for the control and study groups, respectively, and the difference between these groups was statistically significant (p=0.007).Conclusions: Oral administration of LFE appears to have a preventive effect against the inflammatory responses and TNF- expression induced by transurethral instillation of LPS in the mouse bladder. Further studies are required to determine the clinical application of this finding.
Abstract
Purpose: The effects of Lactobacillus fermentation extract (LFE) on cystitis induced by Escherichia coli lipopolysaccharide (LPS) in the mouse bladder were investigated by pathological analyses and measurement of the levels of tumor necrosis factor-alpha (TNF-) and interleukin-18 (IL-18).Materials and Methods: LFE was administered orally (5 g/L) to mice for 10 days after which the study group (n=12) received transurethral injection of 5 g/L LPS. The bladder tissue was then harvested after 24 hours and subjected to hematoxylin and eosin staining. A semi-quantitative score was used to evaluate inflammation (bladder inflammation index, BII). TNF- immunohistochemical staining and multiplex cytokine assays were also performed. TNF- and IL-18 levels were determined. The results were compared with those of the control group (n=12).Results: The BII in the control and study groups was 2.7±0.5 and 1.1±0.7, respectively, with the control group scores differing significantly from the study group scores (p<0.001). TNF- immunohistochemical staining results were similar. The TNF- levels determined by the multiplex cytokine assay were 2.82±1.35 pg/mg and 1.55±0.56 pg/mg for the control and study groups, respectively, and the difference between these groups was statistically significant (p=0.007).Conclusions: Oral administration of LFE appears to have a preventive effect against the inflammatory responses and TNF- expression induced by transurethral instillation of LPS in the mouse bladder. Further studies are required to determine the clinical application of this finding.
참고문헌 (28)
- 배현주, "지역사회 단순 요로감염에서의 항생제 내성 및 최신 치료", 대한내과학회지, 81(6), pp.685~689 (2011), 대한내과학회
- 김태형, "단순방광염의 경험치료제의 선택: 더 이상 가능하지 않은 무임승차", Infection and Chemotherapy, 44(4), pp.323~327 (2012), 대한감염학회
- Barrons R, "Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review", Clin Ther, 30, pp.453~468 (2008)
- 유광호, "최근 요로감염증의 주요 원인균과 항생제 감수성에 관한 고찰", Investigative and Clinical Urology, 48(6), pp.638~645 (2007), 대한비뇨의학회
- 김희연, "중환자 집중 치료실에서 발생하는 요로감염의 주요 원인균과 항생제 감수성의 변화", Investigative and Clinical Urology, 50(11), pp.1108~1113 (2009), 대한비뇨의학회
- Olson NC, "Dodam JR. Mediators and vascular effects in response to endotoxin", Br Vet J, 151, pp.489~522 (1995)
- Jerde TJ, "Determination of mouse bladder inflammatory response to E. coli lipopolysaccharide", Urol Res, 28, pp.269~273 (2000)
- Saban MR, "LPS-sensory peptide communication in experimental cystitis", Am J Physiol Renal Physiol, 282, pp.F202~F210 (2002)
- Gracie JA, "Interleukin-18", J Leukoc Biol, 73, pp.213~224 (2003)
- Hochholzer P, "Role of interleukin-18 (IL-18) during lethal shock: decreased lipopolysaccharide sensitivity but normal superantigen reaction in IL-18-deficient mice", Infect Immun, 68, pp.3502~3508 (2000)
- Smaldone MC, "Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis", Urology, 73, pp.421~426 (2009)
- Corcoran AT, "Mapping the cytokine profile of painful bladder syndrome", interstitial cystitis in human bladder and urine specimens, 2013, pp.31, 241~246
- Lewis RE, "Error of intraperitoneal injections in rats", Lab Anim Care, 16, pp.505~509 (1966)
- Larsson PG, "Bacterial vaginosis--a disturbed bacterial flora and treatment enigma", APMIS, 113, pp.305~316 (2005)
- 이남석, "E. coli 요로감염 흰쥐 모델에서 유산균 요로 투여의 항균 효과: 예보", Investigative and Clinical Urology, 50(12), pp.1253~1257 (2009), 대한비뇨의학회
- Asahara T, "Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection", Antimicrob Agents Chemother, 45, pp.1751~1760 (2001)
- Kontiokari T, "Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women", BMJ, 322, pp.1571~ (2001)
- 이승주, "Lipopolysaccharide로 유발된 방광염 생쥐모델에서 경구용 Escherichia coli 추출물의 방광내 면역증강효과 및 방광염 예방효과", Investigative and Clinical Urology, 45(10), pp.1049~1055 (2004), 대한비뇨의학회
- 이정원, "Cyclophosphamide로 유발된 백서 방광염에서 Hyaluronic Acid의 방광보호 효과", Investigative and Clinical Urology, 50(8), pp.797~804 (2009), 대한비뇨의학회
- Schiffrin EJ, "Donnet- Hughes A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria", J Dairy Sci, 78, pp.491~497 (1995)
- Fischer S, "Stimulation of the specific immune system by mistletoe extracts", Anticancer Drugs, Suppl 1, pp.S33~S37 (1997)
- Hathout AS, "Ability of Lactobacillus casei and Lactobacillus reuteri to protect against oxidative stress in rats fed aflatoxinscontaminated diet", Toxicon, 58, pp.179~186 (2011)
- Kim HJ, "A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating", Neurogastroenterol Motil, 17, pp.687~696 (2005)
- Takano T, "Anti-hypertensive activity of fermented dairy products containing biogenic peptides", Antonie Van Leeuwenhoek, 82, pp.333~340 (2002)
- Meisel H, "Bioactive peptides encrypted in milk proteins: proteolytic activation and thropho-functional properties", Antonie Van Leeuwenhoek, 76, pp.207~215 (1999)
- Leblanc J, "Induction of a humoral immune response following an Escherichia coli O157:H7 infection with an immunomodulatory peptidic fraction derived from Lactobacillus helveticus-fermented milk", Clin Diagn Lab Immunol, 11, pp.1171~1181 (2004)
- Thomas CM, "Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling", PLoS One, 7, pp.e31951~ (2012)
- Stein PC, "Bladder injury model induced in rats by exposure to protamine sulfate followed by bacterial endotoxin", J Urol, 155, pp.1133~1138 (1996)